Results 141 to 150 of about 134,167 (281)
Abstract Purpose To determine the relationship between the baseline junctional retinal sensitivity measured with microperimetry and the atrophy progression rate in eyes with geographic atrophy (GA) secondary to age‐related macular degeneration. Methods In this prospective cohort study, patients with GA were examined with fundus autofluorescence (FAF ...
Alexander Kai Thomsen +5 more
wiley +1 more source
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider +7 more
wiley +1 more source
What’s new in age-related macular degeneration?
Introduction Age-related macular degeneration (AMD) was regarded as unimportant in global blindness, of relevance only to the minority of the world’s population that live in wealthy countries. However, increasing life expectancy, particularly in Asia,
David Yorston
doaj
Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola +3 more
wiley +1 more source
New perspectives on VEGF signalling in Alzheimer's disease
Emery et al. bring together findings from recent multi‐omic studies, including single‐cell mRNA analysis of human post‐mortem brain tissue, and proteomic analysis of matched CSF and blood samples in large clinical studies. The authors present evidence of the involvement of altered VEGF signalling in vascular and immune dysfunction and neurodegeneration
Cherelle E. G. Emery +2 more
wiley +1 more source
New developments in age-related macular degeneration
The World Health Organization (WHO) estimates that over 3 million people (9% of global blindness) are blinded by age-related macular degeneration (AMD). AMD affects people over the age of 55. There are two main types of AMD, dry and wet.
Lyndon da Cruz
doaj
The genetics of age-related macular degeneration.
Age-related macular degeneration (AMD) is increasingly recognized as a complex genetic disorder in which one or more genes contribute to an individual's susceptibility for developing the condition. Twin and family studies as well as population-based genetic epidemiologic methods have convincingly demonstrated the importance of genetics in AMD, though ...
Gorin, M.B. +6 more
openaire +3 more sources
Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms
The Mediterranean diet (MedDiet) is among the most extensively studied dietary patterns and has been consistently associated with reduced risk of all‐cause mortality, cardiovascular disease, metabolic disorders, cognitive decline and several types of cancers.
Lukas Schwingshackl +3 more
wiley +1 more source
Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies +8 more
wiley +1 more source
ABSTRACT Background This retrospective multicenter longitudinal analysis analysed the loss trajectory of best recorded visual acuity (BRVA) and Goldmann visual field (GVF) in RPGR‐associated retinal degeneration (RPGR‐RD). Methods Patients with genetically confirmed RPGR‐RD were classified into rod‐cone (RC), cone/cone‐rod (CR) and female‐carrier ...
Bela J. Parekh +52 more
wiley +1 more source

